Barclays Downgrades SpringWorks Therapeutics to Equal-Weight, Lowers Price Target to $47
Author: Benzinga Newsdesk | April 28, 2025 12:28pm
Barclays analyst Peter Lawson downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Overweight to Equal-Weight and lowers the price target from $63 to $47.